Abstract
e17028Background: Ribociclib is a potent and selective cyclin-dependent kinase (CDK) 4/6 inhibitor with significant pre-clinical activity in enzalutamide-resistant prostate cancer cell lines. Prior...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have